Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses

人类呼吸道合胞病毒和其他肺病毒的实验室研究

• 批准号: 8745290
• 负责人: PETER LEON COLLINS
• 金额: $ 191.68万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745290
• 关键词: Acetylglucosamine; Affect; Age; Age-Months; Amino Acids; Animals; Antigens; Antiviral Agents; Antiviral Therapy; Arsenites; Attenuated; Attenuated Live Virus Vaccine; Basic Science; Binding; Biology; Cell physiology; Cercopithecus pygerythrus; Child; Childhood; Clinical Trials; Cloning; Code; Codon Nucleotides; Complementary DNA; Cytoplasm; Cytoplasmic Granules; Development; Elderly; Electrons; Elongation Factor; Enzymes; Evaluation; Exhibits; FDA approved; Family; Gene Deletion; Genes; Genetic; Genetic Code; Genetic Transcription; Genetic Variation; Genome; Glycoproteins; Goals; Growth; Hand; Human Metapneumovirus; Human poliovirus; Human respiratory syncytial virus; Immunity; Immunocompromised Host; In Vitro; Inclusion Bodies; Individual; Inflammatory; Inflammatory Response; Laboratory Study; Left; Life; Link; Lower respiratory tract structure; MAP Kinase Gene; MAPK14 gene; Messenger RNA; Methods; Missense Mutation; Mitogen-Activated Protein Kinases; Molecular; Molecular Biology; Molecular Genetics; Morbidity - disease rate; Mus; Mutation; Nature; Nonstructural Protein; Nucleocapsid; Nucleoproteins; Nucleotides; Open Reading Frames; Oxidative Stress; PTPN11 gene; Paramyxovirus; Phenotype; Phosphoproteins; Phosphorylation; Physiological; Play; Pneumovirus; Polioviruses; Polymerase; Polymerase Gene; Population; Protein Kinase; Proteins; RNA; RNA Viruses; RNA chemical synthesis; Reagent; Recombinant DNA; Recombinants; Refractory; Reporting; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; Respiratory Tract Diseases; Respiratory syncytial virus; Respiratory syncytial virus RSV proteins; Ribosomes; Role; Serial Passage; Signal Pathway; Signal Transduction; Site; Stress; Stress Tests; Structure; System; TIS11 protein; Temperature; Time; Transcription Elongation; Transfer RNA; Transferase; Translations; Vaccine Design; Vaccines; Viral; Viral Genome; Viral Inclusion Bodies; Viral Proteins; Virus; Virus Diseases; Work; Zinc; attenuation; base; biological adaptation to stress; clinical lot; design; genome sequencing; glycoprotein G; human MAPK14 protein; improved; influenzavirus; mRNA Stability; mitogen-activated protein kinase p38; mortality; multiple myeloma M Protein; mutant; novel vaccines; pathogen; phase 1 study; positional cloning; preclinical study; research and development; research clinical testing; response; vaccine candidate; vaccine development; viral RNA

RSV and HMPV are cytoplasmic enveloped RNA viruses of the paramyxovirus family. Their genomes are single strands of negative-sense RNA of 15.2 kb (RSV) and 13.3 kb (HMPV) that encode 10 mRNAs and 11 unique proteins (RSV) or 8 mRNAs and 9 unique proteins (HMPV). Each virus encodes a nucleoprotein N, phosphoprotein P, matrix protein M, small hydrophobic protein SH, major glycoprotein G, fusion glycoprotein F, M2-1 and M2-2 polymerase factors, and polymerase L. In addition, RSV encodes two nonstructural proteins NS1 and NS2. 
We have been working to develop attenuating mutations in RSV that have improved genetic and phenotypic stability, for the purpose of producing live-attenuated vaccine strains with increased stability. In one approach, we worked to create attenuating mutations by deleting one or several codons at a given locus in coding sequence in the viral genome, using known missense mutations as a guide. Most of the attempted codon-deletions proved to be lethal to the virus, but we found that deletion of codon 1313 in the L polymerase gene (del1313) resulted in a virus that replicated with wt-like efficiency at the permissive temperature of 32C but was restricted at 37C. In addition, it was restricted 50-fold and 150-fold in the upper and lower respiratory tract, respectively, of mice. We combined this del1313 mutation with the previously described attenuating NS2 gene deletion (delNS2) to produce the recombinant live-attenuated RSV vaccine candidate delNS2/del1313. During in vitro stress tests involving serial passage at incrementally increasing temperatures to evaluate genetic stability, a second-site compensatory mutation was detected in close proximity of del1313, namely I1314T. This site was genetically and phenotypically stabilized by an I1314L substitution. Combination of I1314L with delNS2/del1313 yielded genetic stability at physiological temperature. This stabilized vaccine candidate was moderately temperature-sensitive and had a level of restriction in experimental animals comparable to that of MEDI-559 and RSV cps2, two promising RSV vaccine candidate that presently are in or entering clinical trials. The level of attenuation and the genetic stability of delNS2/del1313 indicate that it is a promising candidate suitable for evaluation in pediatric phase I studies. This virus has been manufactured into a clinical lot and has been approved by the FDA for studies beginning this year in seropositive children 6-59 months of age. 
 We evaluated the strategy of codon-pair deoptimization (CPD) as a means of developing genetically and phenotypically stable attenuated RSV strains. It is well known that there is a bias in codon-pair usage in nature. Specifically, any given pair of amino acids has the possibility to be encoded by a variety of different combinations of synonymous codons due to the degeneracy of the genetic code, but the observed usage of codon-pairs typically is biased to favor a subset of the possible combinations. One factor in this bias is thought to be translational efficiency and accuracy, because certain combinations of tRNA pairs are favored at the A and P sites in the ribosome due to tRNA geometry and other factors. CPD involves the deliberate introduction of under-represented synonymous codon-pairs into numerous sites in protein-coding sequence to achieve sub-optimal expression. These substitutions only involve the ORFS, and thus non-protein-coding genome regions are not affected. Also, CPD involves only synonymous codon substitutions, and thus amino acid coding is unaffected and the antigens remain unchanged. In addition, CPD applied to one or several genes typically involves hundreds or thousands of nucleotide changes, and thus should be highly refractory to de-attenuation. Recently, CPD was applied to poliovirus and influenza virus and was shown to result in attenuated strains. We designed the following set of four CPD RSV genomes in which the indicated ORFs were recoded: (i) Min A; NS1, NS2, N, P, M, and SH (i.e., the left-hand third of the genome); (ii) Min B; G and F (located in the middle of the genome); (iii) Min L; L (located at the right-hand end of the genome); and (iv) Min FLC; all ORFs except M2-1 and M2-2. The recoded genome regions were synthesized commercially and the four CPD viruses were constructed and recovered by reverse genetics. All of the CPD viruses were temperature-sensitive (level of sensitivity: Min FLC>Min L>Min B>Min A) for replication in vitro. This was unexpected given the lack of change in amino acid coding, which was confirmed by re-sequencing. All of the CPD mutants grew less efficiently in vitro than wild type (wt) RSV, even at the permissive temperature of 32C (growth efficiency: wt>Min L>Min A>Min FLC>Min B). Thus, CDP of G and F ORFs provided the greatest effect. The CPD viruses exhibited a range of restriction in mice and African Green Monkeys (AGM) and induced immunity against wt RSV. This study identified new vaccine candidates for RSV and showed that CPD of a nonsegmented negative-strand RNA virus can rapidly generate vaccine candidates with a range of attenuation phenotypes. RSV infection results in the formation of viral inclusion bodies (IBs) that appear as large, prominent, electron-dense structures in the cytoplasm. IBs are thought to be sites of nucleocapsid accumulation and viral RNA synthesis. We found that, during RSV infection, the IBs also were the sites of major sequestration of two proteins involved in cellular signaling pathways. These are phosphorylated p38 mitogen-activated protein kinase (MAPK) (p38-P), a key regulator of cellular inflammatory and stress responses, and O-linked N-acetylglucosamine (OGN) transferase (OGT), an enzyme that catalyzes the post-translational addition of OGN to protein targets to regulate cellular processes including signal transduction, transcription, translation, proteasomal degradation, and the stress response. The virus-induced sequestration of p38-P in viral IBs resulted in a substantial reduction in the accumulation of a downstream signaling substrate, MAPK-activated protein kinase 2 (MK2). Sequestration of OGT in IBs was associated with suppression of stress granule (SG) formation. Thus, while the RSV IBs are thought to play an essential role in viral replication, the present results show that they also play a role in suppressing the cellular response to viral infection. The sequestration of p38-P and OGT in IBs appeared to be reversible: severe oxidative stress resulting from a brief arsenite treatment transformed large IBs into a scattering of smaller bodies, suggestive of partial disassembly, and this was associated with MK2 phosphorylation and OGN-addition. Unexpectedly, the RSV M2-1 protein was found to localize in SGs that formed during oxidative stress. This protein was previously shown to be a viral transcription elongation factor, and the present findings provide the first evidence of possible involvement in SG activities during RSV infection. This involvement is intriguing because the M2-1 protein has some structural similarity - including the presence of a CCCH zinc-binding motif - with the cellular protein tristetraprolin. Tristetraprolin is a SG-associated protein that helps regulate the stability of certain cellular mRNAs including a number encoding pro-inflammatory and antiviral proteins. This suggests a possible role for the viral M2-1 mRNA in mRNA stability.

RSV和HMPV是副粘病毒科的细胞质包膜RNA病毒。它们的基因组是15.2 kb （RSV）和13.3 kb （HMPV）的单链负义RNA，编码10个mrna和11个独特蛋白（RSV）或8个mrna和9个独特蛋白（HMPV）。每个病毒编码一个核蛋白N、磷蛋白P、基质蛋白M、小疏水蛋白SH、主要糖蛋白G、融合糖蛋白F、M2-1和M2-2聚合酶因子和聚合酶l。此外，RSV还编码两个非结构蛋白NS1和NS2。我们一直致力于开发RSV的减毒突变，以提高遗传和表型稳定性，以生产稳定性更高的减毒活疫苗株。在一种方法中，我们利用已知的错义突变作为指导，通过删除病毒基因组编码序列中给定位点上的一个或几个密码子来创建衰减突变。大多数尝试的密码子缺失被证明对病毒是致命的，但我们发现L聚合酶基因（del1313）密码子1313的缺失导致病毒在32℃的允许温度下以wt样的效率复制，但在37℃时受到限制。此外，在小鼠上呼吸道和下呼吸道分别限制50倍和150倍的剂量。我们将del1313突变与先前描述的减毒NS2基因缺失（delNS2）结合，产生了重组的RSV减毒活疫苗候选delNS2/del1313。在体外压力测试中，在逐渐升高的温度下进行连续传代以评估遗传稳定性，在del1313附近检测到第二位点代偿性突变，即I1314T。该位点通过I1314L的替换在遗传和表型上稳定。I1314L与delNS2/del1313组合在生理温度下具有遗传稳定性。这种稳定的候选疫苗对温度适度敏感，并且在实验动物中具有与MEDI-559和RSV cps2相当的限制水平，这两种有希望的RSV候选疫苗目前正在进行或进入临床试验。delNS2/del1313的衰减水平和遗传稳定性表明，它是一个有希望的候选药物，适合在儿科I期研究中进行评估。这种病毒已被制造成临床批次，并已获得FDA批准，从今年开始在6-59个月大的血清阳性儿童中进行研究。& # 8232;